NDA 020392 · Mylan
Cystagon
Cysteamine Bitartrate · Oral
NovelPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Jun 6, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1994
Aug 15, 1994
Approved uses
1
Original approval plus efficacy supplements
Registered trials
33
8 Phase 3, 2 recruiting
FAERS reports
350
237 serious, 34 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 16, 2021.
INDICATIONS AND USAGE CYSTAGON ® is indicated for the management of nephropathic cystinosis in children and adults.
Mechanism: Mechanism of Action Cystinosis is an autosomal recessive inborn error of metabolism in which the transport of cystine out of lysosomes is abnormal; in the nephropathic form, accumulation of cystine and formation of crystals damage various organs, especially the kidney, leading to renal tubular Fanconi Syndrome and progressive glomerular failure, with end stage renal failure by the end of the first decade of life. In four studies of cystinosis patients before cysteamine was available, renal death (need for transplant or dialysis) occurred at median age of less than 10 years. Patients with...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 15, 1994 Original approval · Type 1 - New Molecular Entity · priority review
2 products under this application
- CYSTAGON · CYSTEAMINE BITARTRATE EQ 50MG BASE · CAPSULE, ORAL · Prescription
- CYSTAGON · CYSTEAMINE BITARTRATE EQ 150MG BASE · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Cysteamine Bitartrate" as an intervention, any sponsor and status, largest first.
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
National Eye Institute (NEI)NIH
NCT00001213 · 328 participants · Start Apr 1986 · Primary completion Jul 2013
Drug: Cysteamine · For: Cystinosis
Sites: Bethesda, Maryland
Mylan LaboratoriesIndustry
NCT00002110 · 300 participants
Drug: Cysteamine; Zidovudine · For: HIV Infections
Sites: Tampa, Florida; New Orleans, Louisiana; Stony Brook, New York · 6 sites in all
- Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in ChildrenPivotal-lookingCompleted
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT01529268 · 169 participants · Start Jun 2012 · Primary completion Mar 2015
Drug: DR cysteamine bitartrate capsule · For: Nonalcoholic Fatty Liver Disease (NAFLD)
Sites: San Diego, California; San Francisco, California; Atlanta, Georgia · 10 sites in all
- Efficacy and Tolerability of Test Product Versus Cysteamine 5% in Treatment of Facial Epidermal MelasmaPivotal-lookingStatus unknown
Cosmetique Active InternationalIndustry
NCT06278948 · 140 participants (planned) · Start Oct 6, 2023 · Primary completion Jun 2024
Drug: Group CYS · For: Melasma
Sites: Bangalore, India
- Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103)Pivotal-lookingStatus unknown
University Hospital, AngersGovernment (non-federal)
NCT02101957 · 96 participants · Start Oct 2010 · Primary completion Jul 2015
Drug: RP103; Placebo · For: Huntington's Disease
Sites: Angers, France
NovaBiotics Ltd.Industry
NCT03000348 · 91 participants · Start Dec 2016 · Primary completion Apr 2018
Drug: Cysteamine; Placebo Oral Capsule · For: Cystic Fibrosis
Sites: Tucson, Arizona; San Francisco, California; Gainesville, Florida · 17 sites in all
- Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)Pivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT01197378 · 60 participants · Start Aug 27, 2010 · Primary completion Jun 26, 2017
Drug: Cysteamine Bitartrate Delayed-release Capsules · For: Cystinosis
Sites: San Francisco, California; Stanford, California; Atlanta, Georgia · 10 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- vomiting38
- diarrhoea22
- nausea21
- off label use21
- eye irritation17
- abdominal pain15
- treatment noncompliance15
- eye pain14
- headache14
- pneumonia12
- abdominal pain upper11
- decreased appetite11
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 10 |
| 2005 | 2 |
| 2006 | 4 |
| 2007 | 6 |
| 2008 | 7 |
| 2009 | 2 |
| 2010 | 7 |
| 2011 | 7 |
| 2012 | 7 |
| 2013 | 1 |
| 2014 | 26 |
| 2015 | 11 |
| 2016 | 10 |
| 2017 | 24 |
| 2018 | 26 |
| 2019 | 24 |
| 2020 | 26 |
| 2021 | 17 |
| 2022 | 42 |
| 2023 | 33 |
| 2024 | 29 |
| 2025 | 22 |
| 2026 | 7 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cystagon (Cysteamine Bitartrate)
2024 spending
$58K
Beneficiaries
15
119 claims
Per beneficiary
$3,894
$0.83 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $65,489 |
| 2021 | $55,267 |
| 2022 | $60,165 |
| 2023 | $75,219 |
| 2024 | $58,406 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A randomized, double-blind, placebo-controlled trial evaluating cysteamine in Huntington's disease.
Verny C, Bachoud-Lévi AC, Durr A, et al. · Mov Disord 2017 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Targeted Therapies for Leigh Syndrome: Systematic Review and Steps Towards a 'Treatabolome'.
Tiet MY, Lin Z, Gao F, et al. · J Neuromuscul Dis 2021 · Systematic Review
- Alanine Aminotransferase and Gamma-Glutamyl Transpeptidase Predict Histologic Improvement in Pediatric Nonalcoholic Steatohepatitis.
Newton KP, Lavine JE, Wilson L, et al. · Hepatology 2021 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- A systematic literature review of cysteamine bitartrate in the treatment of nephropathic cystinosis.
Medic G, van der Weijden M, Karabis A, et al. · Curr Med Res Opin 2017 · Systematic Review
- Oral cysteamine bitartrate and N-acetylcysteine for patients with infantile neuronal ceroid lipofuscinosis: a pilot study.
Levin SW, Baker EH, Zein WM, et al. · Lancet Neurol 2014 · Clinical Trial, Research Support, N.I.H., Extramural
- CYTE-I-HD: phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease.
Dubinsky R, Gray C · Mov Disord 2006 · Clinical Trial, Phase I, Comparative Study
Sponsor: Mylan
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.